References
- West J, Rodman D M. Gene therapy for pulmonary diseases. Chest 2001; 119: 613–617, [PUBMED], [INFOTRIEVE]
- Prince H M. Gene transfer: a review of methods and applications. Pathology 1998; 30: 335–347, [PUBMED], [INFOTRIEVE], [CSA]
- Friedmann T. Medical ethics. Principles for human gene therapy studies. Science 2000; 287: 2163–2165, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Daniel J C, Smythe W R. Gene therapy of lung cancer. Sem Surg Oncol 2003; 21: 196–204, [CSA], [CROSSREF]
- Roth J A. Modification of tumor suppressor gene expression and induction of apoptosis in non‐small cell lung cancer (NSCLC) with an adenovirus vector expressing wild‐type p53 and cisplatin. Hum Gene Ther 1996; 7: 1013–1030, [PUBMED], [INFOTRIEVE], [CSA]
- Roth J A. Modification of mutant K‐ras gene expression in non‐small cell lung cancer (NSCLC). Hum Gene Ther 1996; 7: 875–889, [PUBMED], [INFOTRIEVE], [CSA]
- Roth J A. Modification of tumor suppressor gene expression in non‐small cell lung cancer (NSCLC) with a retroviral vector expressing wild‐type (normal) p53. Hum Gene Ther 1996; 7: 861–874, [PUBMED], [INFOTRIEVE], [CSA]
- Meazza R, Marciano S, Sforzini S, Orengo A M, Coppolecchia M, Musiani P, Ardizzoni A, Santi L, Azzarone B, Ferrini S. Analysis of IL‐2 receptor expression and of the biological effects of IL‐2 gene transfection in small‐cell lung cancer. Br J Cancer 1996; 74: 788–795, [PUBMED], [INFOTRIEVE]
- Tan Y, Xu M, Wang W, Zhang F, Li D, Xu X, Gu J, Hoffman R M. IL‐2 gene therapy of advanced lung cancer patients. Anticancer Res 1996; 16: 1993–1998, [PUBMED], [INFOTRIEVE], [CSA]
- Zangemeister‐Wittke U, Stahel R A. Novel approaches to the treatment of small‐cell lung cancer. Cell Mol Life Sci 1999; 55: 1585–1598, [CSA], [CROSSREF]
- Greenlee R T, Murray T, Bolden S, Wingo P A. Cancer statistics, CA. Cancer J Clin 2000; 50: 7–33
- Haura E B. Treatment of advanced non‐small‐cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 2001; 8: 326–336, [PUBMED], [INFOTRIEVE]
- Dubinett S M, Miller P W, Sharma S, Batra R K. Gene therapy for lung cancer. Hematol/Oncol Clin North Am 1998; 12: 569–594
- Broker L E, Giaccone G. The role of new agents in the treatment of non‐small cell lung cancer. Eur J Cancer 2002; 38: 2347–2361, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Campling B, El‐Deiry W. Clinical implication of p53 mutation in lung cancer. Mol Biotechnol 2003; 24: 141–156, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rom W N, Tchou‐Wang K M. Functional genomics in lung cancer and biomarker detection. Am J Respir Cell Mol Biol 2003; 29: 153–156, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Robles A I, Wang X W, Harris C C. Drug‐induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53‐mediated apoptotic cell death. Oncogene 1999; 18: 4681–4688, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kim E, Deppert W. The complex interactions of p53 with target DNA: we learn as we go. Biochem Cell Biol 2003; 81: 141–150, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vousden K H. p53: death star. Cell 2000; 103: 691–694, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Roth J A, Nguyen D, Lawrence D D, Kemp B L, Carrasco C H, Ferson D Z, Hong W K, Komaki R, Lee J J, Nesbitt J C, Pisters K M, Putnam J B, Schea R, Shin D M, Walsh G L, Dolormente M M, Han C I, Martin F D, Yen N, Xu K, Stephens L C, McDonnell T J, Mukhopadhyay T, Cai D. Retrovirus‐mediated wild‐type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985–991, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schuler M, Rochlitz C, Horowitz J A, Schlegel J, Perruchoud A P, Kommoss F, Bolliger C T, Kauczor H U, Dalquen P, Fritz M A, Swanson S, Herrmann R, Huber C. A phase I study of adenovirus‐mediated wild‐type p53 gene transfer in patients with advanced non‐small cell lung cancer. Hum Gene Ther 1998; 9: 2075–2082, [PUBMED], [INFOTRIEVE], [CSA]
- Swisher S G, Roth J A, Nemunaitis J, Lawrence D D, Kemp B L, Carrasco C H, Connors D G, El‐Naggar A K, Fossella F, Glisson B S, Hong W K, Khuri F R, Kurie J M, Lee J J, Lee J S, Mack M, Merritt J A, Nguyen D M, Nesbitt J C, Perez‐Soler R, Pisters K M, Putnam J B, Jr, Richli W R, Savin M, Waugh M K. Adenovirus‐mediated p53 gene transfer in advanced non‐small‐cell lung cancer. J Natl Cancer Inst 1999; 91: 763–771, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schuler M, Herrmann R, De Greve J L, Stewart A K, Gatzemeier U, Stewart D J, Laufman L, Gralla R, Kuball J, Buhl R, Heussel C P, Kommoss F, Perruchoud A P, Shepherd F A, Fritz M A, Horowitz J A, Huber C, Rochlitz C. Adenovirus‐mediated wild‐type p53 gene transfer in patients receiving chemotherapy for advanced non‐small‐cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750–1758, [PUBMED], [INFOTRIEVE]
- Nemunaitis J, Swisher S G, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence D D, Kemp B L, Fossella F, Glisson B S, Hong W K, Khuri F R, Kurie J M, Lee J J, Lee J S, Nguyen D M, Nesbitt J C, Perez‐Soler R, Pisters K M, Putnam J B, Richli W R, Shin D M, Walsh G L, Merritt J, Roth J. Adenovirus‐mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non‐small‐cell lung cancer. J Clin Oncol 2000; 18: 609–622, [PUBMED], [INFOTRIEVE]
- Swisher S G, Roth J A, Komaki R, Gu J, Lee J J, Hicks M, Ro J Y, Hong W K, Merritt J A, Ahrar K, Atkinson N E, Correa A M, Dolormente M, Dreiling L, El‐Naggar A K, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri F R, Kurie J M, Liao Z, McDonnell T J, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters K M, Putnam J B, Jr, Sarabia A J, Shelton T, Stevens C, Shin D M, Smythe W R, Vaporciyan A A, Walsh G L, Yin M. Induction of p53‐regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9: 93–101, [PUBMED], [INFOTRIEVE], [CSA]
- Patuck A J, Belldegrun A S. Phase I clinical trial of interleukin. Curr Opin Mol Ther 2001; 2: 33
- Figlin R A, Parker S E, Horton H M. Technology evaluation: interleukin‐2 gene therapy for the treatment of renal cell carcinoma. Curr Opin Mol Ther 1999; 1: 271–278, [PUBMED], [INFOTRIEVE], [CSA]
- Schmidt‐Wolf I G, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft H G, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin‐2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999; 81: 1009–1016, [CROSSREF]
- Mahvi D M, Sondel P M, Yang N S, Albertini M R, Schiller J H, Hank J, Heiner J, Gan J, Swain W, Logrono R. Phase I/IB study of immunization with autologous tumor cells transfected with the GM‐CSF gene by particle‐mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther 1997; 8: 875–891, [PUBMED], [INFOTRIEVE], [CSA]
- Sterman D H, Treat J, Litzky L A, Amin K M, Coonrod L, Molnar‐Kimber K, Recio A, Knox L, Wilson J M, Albelda S M, Kaiser L R. Adenovirus‐mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083–1092, [PUBMED], [INFOTRIEVE], [CSA]
- Reed J C. Double identity for proteins of the Bcl‐2 family. Nature 1997; 387: 773–776, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Johnson L G, Boucher R C. Strategies for gene therapy of cystic fibrosis. Gene Therapy in Lung Disease, S M Albelda. Marcel Dekker Inc., New York 2003; 319–364, 169
- Flotte T R. Gene therapy for α1‐antitrypsin deficiency. Gene Therapy in Lung Disease, S M Albelda. Marcel Dekker Inc., New York 2003; 407–418, 169
- Griesenbach U, Ferrari S, Geddes D M, Alton E W. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2002; 9: 1344–1350, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brigham K L, Lane K B, Meyrick B, Stecenko A A, Strack S, Cannon D R, Caudill M, Canonico A E. Transfection of nasal mucosa with a normal alpha1‐antitrypsin gene in alpha1‐antitrypsin‐deficient subjects: comparison with protein therapy. Hum Gene Ther 2000; 11: 1023–1032, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Stecenko A A, Brigham K L. Gene therapy progress and prospects: alpha‐1 antitrypsin. Gene Ther 2003; 10: 95–99, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cassileth P A, Podack E, Sridhar K, Savaraj N, Hanlon J. Phase I study of transfected cancer cells expressing the interleukin‐2 gene product in limited stage small cell lung cancer. Hum Gene Ther 1995; 6: 369–383, [PUBMED], [INFOTRIEVE], [CSA]
- Zabner J, Cheng S H, Meeker D, Launspach J, Balfour R, Perricone M A, Morris J E, Marshall J, Fasbender A, Smith A E, Welsh M J. Comparison of DNA‐lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest 1997; 100: 1529–1537, [PUBMED], [INFOTRIEVE], [CSA]
- Noone P G, Hohneker K W, Zhou Z, Johnson L G, Foy C, Gipson C, Jones K, Noah T L, Leigh M W, Schwartzbach C, Efthimiou J, Pearlman R, Boucher R C, Knowles M R. Safety and biological efficacy of a lipid–CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Molec Ther 2000; 1: 105–114, [CSA], [CROSSREF]
- Porteous D J, Dorin J R, McLachlan G, Davidson‐Smith H, Davidson H, Stevenson B J, Carothers A D, Wallace W A, Moralee S, Hoenes C, Kallmeyer G, Michaelis U, Naujoks K, Ho L P, Samways J M, Imrie M, Greening A P, Innes J A. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4: 210–218, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Boucher R C, Knowles M R, Johnson L G, Olsen J C, Pickles R, Wilson J M, Engelhardt J, Yang Y, Grossman M. Gene therapy for cystic fibrosis using E1‐deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. Hum Gene Ther 1994; 5: 615–639, [PUBMED], [INFOTRIEVE], [CSA]
- Crystal R G, Jaffe A, Brody S, Mastrangeli A, McElvaney N G, Rosenfeld M, Chu C S, Danel C, Hay J, Eissa T. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Hum Gene Ther 1995; 6: 643–666, [PUBMED], [INFOTRIEVE], [CSA]
- Crystal R G, McElvaney N G, Rosenfeld M A, Chu C S, Mastrangeli A, Hay J G, Brody S L, Jaffe H A, Eissa N T, Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42–51, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Welsh M J, Smith A E, Zabner J, Rich D P, Graham S M, Gregory R J, Pratt B M, Moscicki R A. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium. Hum Gene Ther 1994; 5: 209–219, [PUBMED], [INFOTRIEVE], [CSA]
- Welsh M J, Zabner J, Graham S M, Smith A E, Moscicki R, Wadsworth S. Adenovirus‐mediated gene transfer for cystic fibrosis: part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus. Hum Gene Ther 1995; 6: 205–218, [PUBMED], [INFOTRIEVE], [CSA]
- Gene therapy for cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways. A phase I study. Hum Gene Ther 1994; 5: 1019–1057, [CSA]
- Wilson J M, Engelhardt J F, Grossman M, Simon R H, Yang Y. Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a phase I trial. Hum Gene Ther 1994; 5: 501–519, [PUBMED], [INFOTRIEVE], [CSA]
- Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R. A phase I study of an adeno‐associated virus‐CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7: 1145–1159, [PUBMED], [INFOTRIEVE], [CSA]
- Wagner J A, Moran M L, Messner A H, Daifuku R, Conrad C K, Reynolds T, Guggino W B, Moss R B, Carter B J, Wine J J, Flotte T R, Gardner P. A phase I/II study of tgAAV‐CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther 1998; 9: 889–909, [PUBMED], [INFOTRIEVE], [CSA]
- Wagner J A, Nepomuceno I B, Messner A H, Moran M L, Batson E P, Dimiceli S, Brown B W, Desch J K, Norbash A M, Conrad C K, Guggino W B, Flotte T R, Wine J J, Carter B J, Reynolds T C, Moss R B, Gardner P. A phase II, double‐blind, randomized, placebo‐controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13: 1349–1359, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zuckerman J B, Robinson C B, McCoy K S, Shell R, Sferra T J, Chirmule N, Magosin S A, Propert K J, Brown‐Parr E C, Hughes J V, Tazelaar J, Baker C, Goldman M J, Wilson J M. A phase I study of adenovirus‐mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Hum Gene Ther 1999; 10: 2973–2985, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Bellon G, Michel‐Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, Accart N, Layani M P, Aymard M, Bernon H, Bienvenu J, Courtney M, Doring G, Gilly B, Gilly R, Lamy D, Levrey H, Morel Y, Paulin C, Perraud F, Rodillon L, Sene C, So S, Touraine‐Moulin F, Pavirani A, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997; 8: 15–25, [PUBMED], [INFOTRIEVE], [CSA]
- Aitken M L, Moss R B, Waltz D A, Dovey M E, Tonelli M R, McNamara S C, Gibson R L, Ramsey B W, Carter B J, Reynolds T C. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001; 12: 1907–1916, [PUBMED], [INFOTRIEVE], [CSA]
- Flotte T R, Zeitlin P L, Reynolds T C, Heald A E, Pedersen P, Beck S, Conrad C K, Brass‐Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter B J, Guggino W B. Phase I trial of intranasal and endobronchial administration of a recombinant adeno‐associated virus serotype 2 (rAAV2)‐CFTR vector in adult cystic fibrosis patients: a two‐part clinical study. Hum Gene Ther 2003; 14: 1079–1088, [PUBMED], [INFOTRIEVE], [CSA]
- Knowles M R, Noone P G, Hohneker K, Johnson L G, Boucher R C, Efthimiou J, Crawford C, Brown R, Schwartzbach C, Pearlman R. A double‐blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid–DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Hum Gene Ther 1998; 9: 249–269, [PUBMED], [INFOTRIEVE], [CSA]
- Suzuki M, Matsuse T, Isigatsubo Y. Gene therapy for lung diseases: development in the vector biology and novel concepts for gene therapy applications. Curr Mol Med 2001; 1: 67–79, [PUBMED], [INFOTRIEVE], [CSA]
- Perricone M A, Morris J E, Pavelka K, Plog M S, O'Sullivan B P, Joseph P M, Dorkin H, Lapey A, Balfour R, Meeker D P, Smith A E, Wadsworth S C, St George J A. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther 2001; 12: 1383–1394, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vadolas J, Williamson R, Ioannou P A. Gene therapy for inherited lung disorders: an insight into pulmonary defence. Pulm Pharmacol Ther 2002; 15: 61–72, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Driskell R A, Engelhardt J F. Current status of gene therapy for inherited lung diseases. Annu Rev Physiol 2003; 65: 585–612, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kootstra N A, Verma I M. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 2003; 43: 413–439, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Duan D, Yue Y, Engelhardt J F. Expanding AAV packaging capacity with trans‐splicing or overlapping vectors: a quantitative comparison. Molec Ther 2001; 4: 383–391, [CSA], [CROSSREF]
- Caplen N J, Alton E W, Middleton P G, Dorin J R, Stevenson B J, Gao X, Durham S R, Jeffery P K, Hodson M E, Coutelle C, et al. Liposome‐mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995; 1: 39–46, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 2003; 89: 237–249, [PUBMED], [INFOTRIEVE], [CSA]
- Gan K H, Veeze H J, van den Ouwel A M, Halley D J, Scheffer H, van der Hout A, Overbeek S E, de Jongste J C, Bakker W, Heijerman H G. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995; 333: 95–99, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wodarz D. Gene therapy for killing p53‐negative cancer cells: use of replicating versus nonreplicating agents. Hum Gene Ther 2003; 14: 153–159, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wang A, Huang H, Li S. Therapeutic effect of AdCMVCD/5‐FC system and metabolism of 5‐FC in the treatment of human tongue squamous cell carcinoma. Chin Med J (Engl) 2003; 116: 248–252, [CSA]
- St George J A. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003; 10: 1135–1141, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Vorburger S A, Hunt K K. Adenoviral gene therapy. Oncologist 2002; 7: 46–59, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kay M A, Holterman A X, Meuse L, Gown A, Ochs H D, Linsley P S, Wilson C B. Long‐term hepatic adenovirus‐mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191–197, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yang Y, Wilson J M. Clearance of adenovirus‐infected hepatocytes by MHC class I‐restricted CD4 + CTLs in vivo. J Immunol 1995; 155: 2564–2570, [PUBMED], [INFOTRIEVE]
- Kochanek S, Schiedner G, Volpers C. High‐capacity ‘gutless’ adenoviral vectors. Curr Opin Mol Ther 2001; 3: 454–463, [PUBMED], [INFOTRIEVE], [CSA]
- Herweijer H, Wolff J A. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 2003; 10: 453–458, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9: 1647–1652, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ruiz F E, Clancy J P, Perricone M A, Bebok Z, Hong J S, Cheng S H, Meeker D P, Young K R, Schoumacher R A, Weatherly M R, Wing L, Morris J E, Sindel L, Rosenberg M, van Ginkel F W, McGhee J R, Kelly D, Lyrene R K, Sorscher E J. A clinical inflammatory syndrome attributable to aerosolized lipid–DNA administration in cystic fibrosis. Hum Gene Ther 2001; 12: 751–761, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jain V, Kitagaki K, Kline J. CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy 2003; 33: 1330–1335, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Robbins P D, Ghivizzani S C. Viral vectors for gene therapy. Pharmacol Ther 1998; 80: 35–47, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ferrari S, Griesenbach U, Geddes D M, Alton E. Immunological hurdles to lung gene therapy. Clin Exp Immunol 2003; 132: 1–8, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Scheule R K, St George J A, Bagley R G, Marshall J, Kaplan J M, Akita G Y, Wang K X, Lee E R, Harris D J, Jiang C, Yew N S, Smith A E, Cheng S H. Basis of pulmonary toxicity associated with cationic lipid‐mediated gene transfer to the mammalian lung. Hum Gene Ther 1997; 8: 689–707, [PUBMED], [INFOTRIEVE], [CSA]
- Gautam A, Densmore C L, Waldrep J C. Pulmonary cytokine responses associated with PEI‐DNA aerosol gene therapy. Gene Ther 2001; 8: 254–257, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chadwick S L, Kingston H D, Stern M, Cook R M, O'Connor B J, Lukasson M, Balfour R P, Rosenberg M, Cheng S H, Smith A E, Meeker D P, Geddes D M, Alton E W. Safety of a single aerosol administration of escalating doses of the cationic lipid GL‐67/DOPE/DMPE‐PEG5000 formulation to the lungs of normal volunteers. Gene Ther 1997; 4: 937–942, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Alton E W, Stern M, Farley R, Jaffe A, Chadwick S L, Phillips J, Davies J, Smith S N, Browning J, Davies M G, Hodson M E, Durham S R, Li D, Jeffery P K, Scallan M, Balfour R, Eastman S J, Cheng S H, Smith A E, Meeker D, Geddes D M. Cationic lipid‐mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double‐blind placebo‐controlled trial. Lancet 1999; 353: 947–954, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Buchschacher G L, Jr. Introduction to retroviruses and retroviral vectors. Somat Cell Mol Genet 2001; 26: 1–11, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Quinonez R, Sutton R E. Lentiviral vectors for gene delivery into cells. DNA Cell Biol 2002; 21: 937–951, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 2003; 21: 117–122, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jakobsson J, Ericson C, Rosenqvist N, Lundberg C. Lentiviral vectors. Int Rev Neurobiol 2003; 55: 111–122, [PUBMED], [INFOTRIEVE], [CSA]
- Roy I. Ethical considerations in the use of lentiviral vectors for genetic transfer. Somat Cell Mol Genet 2001; 26: 175–191, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Davies J C, Geddes D M, Alton E. Pulmonary gene therapy. Pharmaceutical Gene Delivery Systems, A Rolland, S M Sullivan. Marcel Dekker Inc., New York 2003; 363–397, 131
- Goldman M J, Wilson J M. Expression of alpha v beta 5 integrin is necessary for efficient adenovirus‐mediated gene transfer in the human airway. J Virol 1995; 69: 5951–5958, [PUBMED], [INFOTRIEVE], [CSA]
- Walters R W, Grunst T, Bergelson J M, Finberg R W, Welsh M J, Zabner J. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem 1999; 274: 10219–10226, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, Steel R, Scheid P, Zhu J, Jeffery P K, Kato A, Hasan M K, Nagai Y, Masaki I, Fukumura M, Hasegawa M, Geddes D M, Alton E W. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18: 970–973, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang L, Peeples M E, Boucher R C, Collins P L, Pickles R J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002; 76: 5654–5666, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ferrari S, Geddes D M, Alton E W. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 2002; 54: 1373–1393, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hodgson S V, Popat S. Polymorphic sequence variants in medicine: a challenge and an opportunity. Clin Med 2003; 3: 260–264, [PUBMED], [INFOTRIEVE]
- Muller M. Pharmacogenomics and drug response. Int J Clin Pharmacol Ther 2003; 41: 231–240, [PUBMED], [INFOTRIEVE]
- Dettweiler U, Simon P. Points to consider for ethics committees in human gene therapy trials. Bioethics 2001; 15: 491–500, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Weiss R A. Virulence and pathogenesis. Trends Microbiol 2002; 10: 314–317, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Horwitz M S. Adenoviruses. Virology, B N Fields, D M Knipe. Raven Press, New York 1990; 1723–1740, 2
- Young L S, Mautner V. The promise and potential hazards of adenovirus gene therapy. Gut 2001; 48: 733–736, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401: 517–518, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Balter M. Gene therapy on trial. Science 2000; 288
- Masuda M, Hanson C A, Dugger N V, Robbins D S, Wilt S G, Ruscetti S K, Hoffman P M. Capillary endothelial cell tropism of PVC‐211 murine leukemia virus and its application for gene transduction. J Virol 1997; 71: 6168–6173, [PUBMED], [INFOTRIEVE], [CSA]
- Garcia‐Sastre A, Durbin R K, Zheng H, Palese P, Gertner R, Levy D E, Durbin J E. The role of interferon in influenza virus tissue tropism. J Virol 1998; 72: 8550–8558, [CSA]
- Haller B L, Barkon M L, Vogler G P, Virgin H Wt. Genetic mapping of reovirus virulence and organ tropism in severe combined immunodeficient mice: organ‐specific virulence genes. J Virol 1995; 69: 357–364, [PUBMED], [INFOTRIEVE], [CSA]
- Lozier J N, Metzger M E, Donahue R E, Morgan R A. The rhesus macaque as an animal model for hemophilia B gene therapy. Blood 1999; 93: 1875–1881, [PUBMED], [INFOTRIEVE], [CSA]
- Duncan S J, Gordon F C, Gregory D W, McPhie J L, Postlethwaite R, White R, Willcox H N. Infection of mouse liver by human adenovirus type. J Gen Virol 1978; 40: 45–61, [PUBMED], [INFOTRIEVE]
- Worgall S, Leopold P L, Wolff G, Ferris B, Van Roijen N, Crystal R G. Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther 1997; 8: 1675–1684, [PUBMED], [INFOTRIEVE], [CSA]
- Worgall S, Wolff G, Falck‐Pedersen E, Crystal R G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37–44, [PUBMED], [INFOTRIEVE], [CSA]
- Cornetta K, Smith F O. Regulatory issues for clinical gene therapy trials. Hum Gene Ther 2002; 13: 1143–1149, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Juengst E T. What next for human gene therapy? Gene transfer often has multiple and unpredictable effects on cells. BMJ 2003; 326: 1410–1411, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pellegrino E D. Trust and distrust in professional ethics. Ethics, Trust and the Professions: Philosophical and Cultural Aspects, E D Pellegrino, R M Veatch, J P Langran. Georgetown Univ Press, Washington 1991
- Kohn D B, Sadelain M, Glorioso J C. Occurrence of leukemia following gene therapy of X‐linked SCID. Nat Rev Cancer 2003; 3: 477–488, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rainsbury J M. Biotechnology on the RAC–FDA/NIH regulation of human gene therapy. Food Drug Law J 2000; 55: 575–600, [PUBMED], [INFOTRIEVE]
- Stolberg S G. The Biotech Death of Jesse Gelsinger. N Y Times Mag, New York 1999; 136–140